{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia&page=103", "query": { "condition": "Leukemia", "page": 103 }, "page_size": 10 }, "pagination": { "page": 103, "page_size": 10, "total_count": 1103, "total_pages": 111, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia&page=104&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia&page=102&page_size=10" }, "source": "local", "last_synced_at": "2026-10-16T01:55:47.738Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04891757", "title": "FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Hematologic Malignancy", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Myelodysplastic Syndromes", "Relapsed Acute Myeloid Leukemia", "Relapsed Chronic Myelomonocytic Leukemia", "Relapsed Myelodysplastic Syndromes" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "FHD-286", "type": "DRUG" }, { "name": "Low Dose Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Foghorn Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 144, "start_date": "2021-06-14", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-07-10", "last_synced_at": "2026-10-15T00:30:39.648Z", "location_count": 5, "location_summary": "Duarte, California • Boston, Massachusetts • New York, New York + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04891757" }, { "nct_id": "NCT03817320", "title": "PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "ALL, Childhood", "Lymphoblastic Leukemia, Acute, Childhood", "Lymphoblastic Lymphoma, Childhood" ], "interventions": [ { "name": "Asparaginase", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Methotrexate (IT)", "type": "DRUG" }, { "name": "Triple IT (Methotrexate, Hydrocortisone, Cytarabine)", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 24, "start_date": "2019-02-12", "completion_date": "2025-06-30", "has_results": true, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-10-15T10:12:58.131Z", "location_count": 17, "location_summary": "Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03817320" }, { "nct_id": "NCT03512405", "title": "Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "CD19 Positive", "Philadelphia Chromosome Positive", "Recurrent Acute Lymphoblastic Leukemia", "Refractory Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2019-08-02", "completion_date": "2025-11-11", "has_results": false, "last_update_posted_date": "2025-05-30", "last_synced_at": "2026-10-14T20:49:29.222Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03512405" }, { "nct_id": "NCT01361711", "title": "Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage I Chronic Lymphocytic Leukemia", "Stage II Chronic Lymphocytic Leukemia", "Stage III Chronic Lymphocytic Leukemia", "Stage IV Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "ofatumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2011-06", "completion_date": "2027-05", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-10-14T04:03:48.255Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01361711" }, { "nct_id": "NCT04730258", "title": "A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AML", "Acute Myeloid Leukemia", "CMML", "Chronic Myelomonocytic Leukemia", "MDS", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "CFI-400945", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Treadwell Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2021-04-16", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-10-01T00:18:29.721Z", "location_count": 6, "location_summary": "Duarte, California • Sacramento, California • Louisville, Kentucky + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04730258" }, { "nct_id": "NCT05179824", "title": "Tempus Priority Study: A Pan-tumor Observational Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Cancer", "Brain Cancer", "Breast Cancer", "Cancer of Bone and Connective Tissue", "Cancer of Cervix", "Cancer of Colon", "Cancer of Endometrium", "Cancer of Esophagus", "Cancer of Gastrointestinal Tract", "Cancer of Head and Neck", "Cancer of Kidney", "Cancer of Larynx", "Cancer of Liver", "Cancer of Rectum", "Cancer of Skin", "Cancer of Stomach", "Cancer of Vulva", "Cancer of the Bile Duct", "Fallopian Tube Cancer", "Leukemia", "Lung Cancer", "Lymphoma", "Ovarian Cancer", "Pancreatic Cancer", "Peritoneal Cancer", "Prostate Cancer", "Spinal Cord Cancer" ], "interventions": [ { "name": "Observation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Tempus AI", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1000, "start_date": "2020-10-19", "completion_date": "2030-10-19", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-10-15T17:40:23.049Z", "location_count": 2, "location_summary": "Dallas, Texas • Houston, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05179824" }, { "nct_id": "NCT02735083", "title": "A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Lymphoid Leukemia" ], "interventions": [ { "name": "UCART19 follow-up", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 28, "start_date": "2021-03-10", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2025-04-11", "last_synced_at": "2026-10-15T18:18:29.066Z", "location_count": 7, "location_summary": "Los Angeles, California • Denver, Colorado • Tampa, Florida + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Charlestown", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02735083" }, { "nct_id": "NCT04072458", "title": "A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Cutaneous T-cell Lymphoma (CTCL)", "DLBCL", "Follicular Lymphoma", "Hodgkin Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Peripheral T-cell Lymphoma (PTCL)", "Small Lymphocytic Lymphoma (SLL)", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "L-Bcl-2 antisense oligonucleotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bio-Path Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-11-05", "completion_date": "2025-04", "has_results": false, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-10-16T01:55:47.738Z", "location_count": 5, "location_summary": "Augusta, Georgia • Valhalla, New York • Nashville, Tennessee + 2 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Valhalla", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04072458" }, { "nct_id": "NCT05885464", "title": "A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoblastic Leukemia", "Lymphoblastic Lymphoma", "T-Cell Lymphoblastic Leukemia/Lymphoma" ], "interventions": [ { "name": "BEAM-201", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Beam Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 5, "start_date": "2023-05-25", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-10-15T03:51:48.987Z", "location_count": 10, "location_summary": "Stanford, California • Denver, Colorado • Chicago, Illinois + 7 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05885464" }, { "nct_id": "NCT03927261", "title": "PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "PRGN-3006 T Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Precigen, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2019-05-20", "completion_date": "2025-08-01", "has_results": false, "last_update_posted_date": "2024-11-08", "last_synced_at": "2026-10-15T23:25:15.315Z", "location_count": 2, "location_summary": "Tampa, Florida • Rochester, Minnesota", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03927261" } ] }